Integral Diagnostics Limited

ASX:IDX Stock Report

Market Cap: AU$701.7m

Integral Diagnostics Valuation

Is IDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDX (A$3) is trading below our estimate of fair value (A$9.7)

Significantly Below Fair Value: IDX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDX?

Key metric: As IDX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IDX. This is calculated by dividing IDX's market cap by their current revenue.
What is IDX's PS Ratio?
PS Ratio1.5x
SalesAU$469.70m
Market CapAU$701.75m

Price to Sales Ratio vs Peers

How does IDX's PS Ratio compare to its peers?

The above table shows the PS ratio for IDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.1x
ACL Australian Clinical Labs
1x4.7%AU$685.1m
CAJ Capitol Health
1.7x6.4%AU$410.4m
HLS Healius
0.6x-4.8%AU$991.2m
HLA Healthia
1xn/aAU$252.1m
IDX Integral Diagnostics
1.5x15.4%AU$701.7m

Price-To-Sales vs Peers: IDX is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does IDX's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.51m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
IDX 1.5xIndustry Avg. 1.3xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IDX is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Oceanic Healthcare industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is IDX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: IDX is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$3.00
AU$3.35
+11.6%
9.4%AU$3.87AU$2.50n/a14
Dec ’25AU$2.92
AU$3.16
+8.3%
9.9%AU$3.72AU$2.50n/a11
Nov ’25AU$2.99
AU$3.16
+5.7%
9.9%AU$3.72AU$2.50n/a11
Oct ’25AU$2.98
AU$3.07
+3.1%
8.1%AU$3.40AU$2.50n/a12
Sep ’25AU$2.60
AU$2.98
+14.7%
7.4%AU$3.40AU$2.50n/a12
Aug ’25AU$2.45
AU$2.72
+10.9%
14.1%AU$3.40AU$2.10n/a12
Jul ’25AU$2.59
AU$2.57
-0.8%
16.0%AU$3.40AU$1.85n/a13
Jun ’25AU$2.44
AU$2.50
+2.6%
17.5%AU$3.60AU$1.85n/a16
May ’25AU$2.46
AU$2.49
+1.1%
17.7%AU$3.60AU$1.85n/a16
Apr ’25AU$2.25
AU$2.49
+10.5%
17.7%AU$3.60AU$1.85n/a16
Mar ’25AU$2.24
AU$2.45
+9.2%
17.4%AU$3.60AU$1.85n/a15
Feb ’25AU$1.94
AU$2.40
+24.2%
20.2%AU$3.60AU$1.70n/a15
Jan ’25AU$1.91
AU$2.51
+32.0%
19.2%AU$3.60AU$1.95n/a16
Dec ’24AU$1.71
AU$2.51
+47.0%
19.2%AU$3.60AU$1.95AU$2.9216
Nov ’24AU$2.65
AU$3.30
+24.4%
6.7%AU$3.60AU$2.75AU$2.9916
Oct ’24AU$2.87
AU$3.27
+13.8%
8.2%AU$3.60AU$2.58AU$2.9817
Sep ’24AU$2.92
AU$3.27
+11.9%
8.2%AU$3.60AU$2.58AU$2.6017
Aug ’24AU$2.96
AU$3.23
+9.2%
11.1%AU$3.70AU$2.58AU$2.4517
Jul ’24AU$3.28
AU$3.18
-3.0%
11.3%AU$3.70AU$2.58AU$2.5918
Jun ’24AU$3.27
AU$3.11
-5.0%
10.9%AU$3.60AU$2.58AU$2.4418
May ’24AU$3.19
AU$3.05
-4.4%
10.4%AU$3.60AU$2.58AU$2.4616
Apr ’24AU$2.94
AU$2.97
+1.0%
10.7%AU$3.60AU$2.50AU$2.2516
Mar ’24AU$2.79
AU$3.00
+7.5%
10.2%AU$3.60AU$2.50AU$2.2416
Feb ’24AU$3.17
AU$3.19
+0.8%
14.5%AU$4.05AU$2.55AU$1.9415
Jan ’24AU$2.93
AU$3.15
+7.5%
13.8%AU$4.05AU$2.55AU$1.9115
Dec ’23AU$2.76
AU$3.16
+14.4%
14.0%AU$4.05AU$2.55AU$1.7114

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 21:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Integral Diagnostics Limited is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
Thomas YeoBarrenjoey Markets Pty Limited
Saul HadassinBarrenjoey Markets Pty Limited